NLS Pharmaceutics (NASDAQ: NLSPW) notes SEC effectiveness for merger

Rhea-AI Filing Summary

NLS Pharmaceutics Ltd. furnished a report stating that on September 10, 2025 it issued a press release titled “Kadimastem and NLS Pharmaceutics Announce Effectiveness of SEC Registration Statement in Connection with Proposed Merger.” The report indicates that a related SEC registration statement for the proposed merger between NLS Pharmaceutics and Kadimastem has become effective, and the press release describing this development is attached as Exhibit 99.1.

Insights

Cross-border M&A and disclosure analyst

NLS highlights SEC registration effectiveness tied to its proposed merger with Kadimastem.

The report from NLS Pharmaceutics Ltd. notes that a U.S. SEC registration statement related to its proposed merger with Kadimastem has become effective, and that this development was communicated via an attached press release dated September 10, 2025. Effectiveness of a registration statement is a procedural milestone in U.S. securities regulation, indicating the filing has cleared SEC review for disclosure purposes.

This step does not itself close the merger or describe its financial terms in the text provided, but it signals progress in the transactional process. Further details on structure, consideration, and next steps would be contained in the underlying registration materials and the referenced press release, which are not reproduced here. Subsequent company communications and regulatory filings would outline completion or changes to the proposed transaction.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of September 2025 (Report No. 2)

Commission file number: 001-39957

NLS PHARMACEUTICS LTD.

(Translation of registrant’s name into English)

The Circle 6

8058 Zurich, Switzerland

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

CONTENTS

On September 10, 2025, NLS Pharmaceutics Ltd. issued a press release titled: “Kadimastem and NLS Pharmaceutics Announce Effectiveness of SEC Registration Statement in Connection with Proposed Merger.” A copy of this press release is furnished herewith as Exhibit 99.1.

1

EXHIBIT INDEX

Exhibit Number		Description of Document
99.1		Press release titled: “Kadimastem and NLS Pharmaceutics Announce Effectiveness of SEC Registration Statement in Connection with Proposed Merger.”

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	NLS Pharmaceutics Ltd.
Date: September 10, 2025	By:	/s/ Alexander Zwyer
		Name:	Alexander Zwyer
		Title:	Chief Executive Officer

3

FAQ

What does the latest Form 6-K from NLSPW (NLS Pharmaceutics) report?

It reports that on September 10, 2025, NLS Pharmaceutics Ltd. issued a press release titled “Kadimastem and NLS Pharmaceutics Announce Effectiveness of SEC Registration Statement in Connection with Proposed Merger,” which is attached as Exhibit 99.1.

What major corporate event involving NLS Pharmaceutics (NLSPW) is mentioned?

The document refers to a proposed merger between Kadimastem and NLS Pharmaceutics Ltd., in connection with which an SEC registration statement has become effective.

What is the significance of the SEC registration statement mentioned by NLS Pharmaceutics?

The report states that a SEC registration statement related to the proposed merger has become effective, indicating that the registration has cleared SEC review for disclosure purposes, as announced in the attached press release.

Which exhibit is included with this NLS Pharmaceutics (NLSPW) Form 6-K?

The Form 6-K includes Exhibit 99.1, a press release titled “Kadimastem and NLS Pharmaceutics Announce Effectiveness of SEC Registration Statement in Connection with Proposed Merger.”

Who signed the NLS Pharmaceutics Form 6-K related to the Kadimastem merger?

The report was signed on behalf of NLS Pharmaceutics Ltd. by Alexander Zwyer, who is identified as the Chief Executive Officer.

Does this NLS Pharmaceutics (NLSPW) filing itself describe the merger terms?

The text provided does not describe the financial or structural terms of the proposed merger; it only notes the effectiveness of the related SEC registration statement and attaches a press release as Exhibit 99.1.